Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Situ Engineering of Tumor Cells as Self-Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Engineered Bacteria-Nanoparticle Conjugate Reprograms Immunosuppressive Niche via Dendritic Cell-Centric Innate-Adaptive Immune Coupling.

ACS nano·2025
Same author

CAR-T therapy dilemma and innovative design strategies for next generation.

Cell death & disease·2025
Same author

CPNE7 promotes colorectal tumorigenesis by interacting with NONO to initiate ZFP42 transcription.

Cell death & disease·2024
Same author

Logic "AND Gate Circuit"-Based Gasdermin Protein Expressing Nanoplatform Induces Tumor-Specific Pyroptosis to Enhance Cancer Immunotherapy.

ACS nano·2024
Same author

mcPGK1-dependent mitochondrial import of PGK1 promotes metabolic reprogramming and self-renewal of liver TICs.

Nature communications·2023
Same journal

Silencing the Signal: The Metastasis Suppressor NDRG1 Disrupts Small Extracellular Vesicle-Mediated Crosstalk in Pancreatic Cancer.

Journal of extracellular vesicles·2026
Same journal

Integrating Nuclear Magnetic Resonance into Bioprocess Control of Clinical-Grade Extracellular Vesicle Manufacturing.

Journal of extracellular vesicles·2026
Same journal

Eliminating PD-L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune-Mediated Tumour Rejection in Mice.

Journal of extracellular vesicles·2026
Same journal

Regulatory Challenges and Opportunities for Cell-Derived Extracellular Vesicles in Pharmaceutical Development: A European and Global Perspective.

Journal of extracellular vesicles·2026
Same journal

ISEV2026 Abstract Book.

Journal of extracellular vesicles·2026
Same journal

Label-Free Clustering Analysis Platform Drives Cascaded Workflow for Scalable Production of Therapeutic Extracellular Vesicles.

Journal of extracellular vesicles·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

In Situ Engineered "Cascade-Amplified" Drug-Loaded Vesicles for Enhanced Cancer Stem Cell Therapy.

Tiantian Zhang1,2, YuanYuan Wei1, Zimai Liu1

  • 1School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Journal of Extracellular Vesicles
|May 10, 2026
PubMed
Summary
This summary is machine-generated.

This study introduces a novel nanoplatform that delivers chemotherapy deep into tumors, targeting cancer stem cells (CSCs). The system enhances anti-tumor immunity by overcoming drug resistance and immune suppression, offering new therapeutic potential.

Keywords:
cancer stem cellsdeep deliveryextracellular vesiclesimmunotherapy

More Related Videos

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
10:03

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Published on: July 5, 2019

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Cancer stem cells (CSCs) drive tumor recurrence and metastasis due to self-renewal and drug resistance.
  • CSCs reside in deep, hypoxic tumor regions, limiting drug penetration and therapeutic efficacy.
  • The CD24/Siglec-10 immune checkpoint axis on CSCs suppresses anti-tumor immune responses.

Purpose of the Study:

  • To develop an in situ engineered, cascade-amplified drug delivery system for deep tumor penetration.
  • To enhance anti-tumor immune responses by overcoming CSC-mediated immune suppression.
  • To achieve synergistic eradication of CSCs and improve immunotherapy outcomes.

Main Methods:

  • A biomimetic core-shell nanoplatform (siXkr8/Dox@PMLC) was engineered for drug delivery.
  • Doxorubicin (Dox) induced apoptotic bodies (ApoBDs) for cascade-amplified drug release.
  • siRNA-mediated silencing of Xkr8 inhibited phosphatidylserine exposure on ApoBDs.
  • Targeted blockade of the CD24/Siglec-10 axis enhanced macrophage phagocytosis of CSCs.

Main Results:

  • The nanoplatform achieved deep drug delivery into CSC-enriched regions.
  • Cascade-amplified apoptosis was established through ApoBD uptake.
  • Inhibition of Xkr8 prevented ApoBD clearance by M2 macrophages, facilitating immune remodeling.
  • CD24/Siglec-10 blockade boosted CSC phagocytosis by macrophages.

Conclusions:

  • The developed nanodelivery system effectively eradicates CSCs via deep drug penetration and cascade amplification.
  • The strategy synergistically enhances anti-tumor immunotherapy by modulating the immune microenvironment.
  • This approach shows significant translational potential for cancer therapy.